Glaucarubin is a quassinoid derived from the tropical shrub, Simarouba glauca.

Glaucarubin has been tested for the treatment of amebiasis, an infection of the intestines caused by Entamoeba histolytica.

[2] In a clinical trial comparing various treatment options for intestinal amoebiasis, patients treated with glaucarubin had a relapse rate of 12%, four times the rate of those treated with emetine–bismuth iodide.

[3] Being a cytotoxin, glaucarubin is capable of killing cells, which is why it has been tested as an anti-cancer drug.

[4] Although it helps in the process of killing the uncontrollable cancer cells, it has the tendency to spread and cause harm to unwanted parts of the body, such as the lymphatic system or the blood stream.